Literature DB >> 32363720

Risk Factors and Center-Level Variation in Hepatocellular Carcinoma Under-Staging for Liver Transplantation.

Nadim Mahmud1,2, Maarouf A Hoteit1, David S Goldberg3.   

Abstract

Liver transplantation (LT) is curative for most patients with hepatocellular carcinoma (HCC). However, 10%-15% of patients experience HCC recurrence. Patients who are reported as within Milan criteria by imaging are frequently found to be outside the criteria on explant. This under-staging of HCC worsens post-LT outcomes. However, risk factors for under-staging have not been elucidated. Furthermore, it is not known if there is regional or center-level variation in under-staging. We conducted a retrospective analysis of adult patients transplanted for HCC in the United Network for Organ Sharing (UNOS) database between 2012 and 2016. Under-staging was determined on the basis of comparing pre-LT imaging to explant findings. Kaplan-Meier methods and Cox regression were used to evaluate the impact of under-staging on HCC recurrence and post-LT survival. Mixed effects logistic regression was used to identify risk factors for under-staging and to study regional and center-level variation in adjusted analyses. A total of 5424 patients were included in the cohort, of whom 24.9% (n = 1353) were under-staged. Post-LT HCC recurrence and death were significantly associated with under-staging (each P < 0.001). In adjusted analyses, independent predictors of under-staging included age (odds ratio [OR], 1.13 per 10 years; 95% confidence interval [CI], 1.03-1.25), male sex (OR, 1.61; 95% CI, 1.36-1.89), down-staging (OR, 4.03; 95% CI, 2.65-6.11), and pre-LT alpha-fetoprotein (P < 0.001). There was also significant variation in under-staging between UNOS regions and among transplant centers, ranging from 14.8% to 38.1%. We report novel risk factors for HCC under-staging, which worsens post-LT outcomes. Significant center-level and regional variation in under-staging highlights the need for standards that achieve greater uniformity in staging.
Copyright © 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2020        PMID: 32363720      PMCID: PMC7897468          DOI: 10.1002/lt.25787

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  30 in total

1.  Optimizing staging for hepatocellular carcinoma before liver transplantation: A retrospective analysis of the UNOS/OPTN database.

Authors:  Richard B Freeman; Abigail Mithoefer; Robin Ruthazer; Khanh Nguyen; Anthony Schore; Ann Harper; Erick Edwards
Journal:  Liver Transpl       Date:  2006-10       Impact factor: 5.799

2.  Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.

Authors:  Nadim Mahmud; Binu John; Tamar H Taddei; David S Goldberg
Journal:  Clin Transplant       Date:  2019-06-25       Impact factor: 2.863

3.  Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging.

Authors:  Matthew S Davenport; Shokoufeh Khalatbari; Peter S C Liu; Katherine E Maturen; Ravi K Kaza; Ashish P Wasnik; Mahmoud M Al-Hawary; Daniel I Glazer; Erica B Stein; Jeet Patel; Deepak K Somashekar; Benjamin L Viglianti; Hero K Hussain
Journal:  Radiology       Date:  2014-02-18       Impact factor: 11.105

4.  Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.

Authors:  Marina Serper; Tamar H Taddei; Rajni Mehta; Kathryn D'Addeo; Feng Dai; Ayse Aytaman; Michelle Baytarian; Rena Fox; Kristel Hunt; David S Goldberg; Adriana Valderrama; David E Kaplan
Journal:  Gastroenterology       Date:  2017-03-07       Impact factor: 22.682

5.  Biases in the reporting of hepatocellular carcinoma tumor sizes on the liver transplant waiting list.

Authors:  Mariya L Samoylova; Mark J Nigrini; Jennifer L Dodge; John P Roberts
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

Review 6.  MELD-based liver allocation: who is underserved?

Authors:  Scott W Biggins; Kiran Bambha
Journal:  Semin Liver Dis       Date:  2006-08       Impact factor: 6.115

7.  An early look at the Organ Procurement and Transplantation Network explant pathology form data.

Authors:  Ann M Harper; Erick Edwards; W Kenneth Washburn; Julie Heimbach
Journal:  Liver Transpl       Date:  2016-06       Impact factor: 5.799

8.  Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Eric Vittinghoff; Francis Y Yao; John Paul Roberts
Journal:  Liver Transpl       Date:  2013-10-21       Impact factor: 5.799

9.  Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria.

Authors:  Samy Kashkoush; Walid El Moghazy; Toshiyasu Kawahara; Boris Gala-Lopez; Christian Toso; Norman M Kneteman
Journal:  Clin Transplant       Date:  2014-05-10       Impact factor: 2.863

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

View more
  3 in total

1.  Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score.

Authors:  David Goldberg; Alejandro Mantero; Craig Newcomb; Cindy Delgado; Kimberly A Forde; David E Kaplan; Binu John; Nadine Nuchovich; Barbara Dominguez; Ezekiel Emanuel; Peter P Reese
Journal:  J Hepatol       Date:  2021-01-13       Impact factor: 30.083

2.  T2 Hepatocellular Carcinoma Exception Policies That Prolong Waiting Time Improve the Use of Evidence-based Treatment Practices.

Authors:  Claire Durkin; David E Kaplan; Therese Bittermann
Journal:  Transplant Direct       Date:  2020-08-21

3.  Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.

Authors:  Neil Mehta; Catherine Frenette; Parissa Tabrizian; Maarouf Hoteit; Jennifer Guy; Neehar Parikh; T Tara Ghaziani; Renu Dhanasekaran; Jennifer L Dodge; Brahma Natarajan; Matthew L Holzner; Leana Frankul; Wesley Chan; Austin Fobar; Sander Florman; Francis Y Yao
Journal:  Gastroenterology       Date:  2021-07-28       Impact factor: 22.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.